Clinical Trial Update: To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) [Phase 2]

View source ↗

Summary

Phase 2 trial of LDE225 (sonidegib) evaluating safety, local tolerability, pharmacokinetics and pharmacodynamics in sporadic superficial and nodular skin basal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Sonidegib (Sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sporadic Superficial and Nodular Skin Basal Cell Carcinomas | Phase 2 | Status: TERMINATED | Results posted: 2015-10-30